KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Dec 2024 value amounting to $196.7 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) fell 0.13% to $196.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.9 million, marking a year-over-year decrease of 0.13%. This contributed to the annual value of $196.7 million for FY2024, which is 2.67% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) stood at $196.7 million, which was up 2.67% from $191.6 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Shares Outstanding (Diluted Average) high stood at $196.7 million for FY2024, and its period low was $182.9 million during FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Shares Outstanding (Diluted Average) value was $191.6 million (recorded in 2023), while the average stood at $192.4 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) rose by 7.06% in 2020, and later dropped by 4.60% in 2021.
  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) (Yearly) stood at $191.7 million in 2020, then fell by 4.60% to $182.9 million in 2021, then increased by 3.34% to $189.0 million in 2022, then climbed by 1.39% to $191.6 million in 2023, then rose by 2.67% to $196.7 million in 2024.